公开(公告)号：US20230167123A1

公开(公告)日：2023-06-01

申请号：US18063575

申请日：2022-12-08

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Grandner ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61P37/06

Abstract: Compounds of formula (I)




wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US12247032B2

公开(公告)日：2025-03-11

申请号：US18063575

申请日：2022-12-08

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Grandner ,  Daniel G. M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: A61P37/06 ,  C07D487/04

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US11453671B2

公开(公告)日：2022-09-27

申请号：US16902499

申请日：2020-06-16

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Grandner ,  Daniel G. M. Shore ,  Marian C. Bryan

IPC: A61K31/519 ,  C07D487/04 ,  A61P11/06 ,  A61K9/00 ,  A61K9/19

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.